ERBB2 and breast carcinoma: In the TransATAC trial, tumors from 774 of the postmenopausal women with HR+/HER2- breast cancer were characterized with the following tests: OncotypeDx, BCI, Prosigna ROR, EPClin, IHC4, and CTS5 (36).